Can ensifentrine-Ohtuvayre be purchased through formal channels in China and purchase advice?

Ensifentrine (trade name: Ohtuvayre™) is the world's first inhaled phosphodiesterase 3/4 dual-target inhibitor, mainly used for the maintenance treatment of adult chronic obstructive pulmonary disease (COPD). The drug was approved by the US FDA in June 2024 and will be commercially available in the United States at the end of August 2024. 2025 In February , Yourui Pharmaceuticals announced that ensefentin was approved in the Macau Special Administrative Region of China for the maintenance treatment of COPD. However, exefantine has not yet been approved in mainland China, and patients who need to use the drug must purchase it from abroad through formal channels.

Currently, exefantine is marketed in the United States and is also sold in pharmacies in Hong Kong. For example, the price of a box of 3mg/2.5mL (60 doses) in a Hong Kong pharmacy is 44,500 Hong Kong dollars. It should be noted that Ensefentin has not yet been approved in mainland China. If patients want to purchase it, they should make sure to choose formal channels to ensure the quality and legality of the drug.

When considering purchasing Exefentine, patients should first consult a professional doctor to confirm whether the drug is suitable for their treatment needs. At the same time, patients should understand information about how to use the drug, possible side effects, and interactions with other drugs. During the purchase process, you should choose a reputable pharmacy or online platform to ensure that the source of the medicine is reliable. In addition, patients should also pay attention to the transportation and storage conditions of medicines to ensure that the medicines are not damaged during transportation.

In short, as a new type of COPD treatment drug, exefantine has not yet been approved in mainland China. However, if patients need to use this drug, they should purchase it from abroad through formal channels and use it under the guidance of professional doctors. At the same time, patients should pay attention to the quality, legality and safety of use of drugs. With mainland China’s response toCOPDWith the continuous review and approval of therapeutic drugs, exefantine is expected to be launched in the Chinese market in the future, providing treatment options for more patients.

Reference materials:https://www.drugs.com/